SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
U.S. and Chinese flags in concrete, broken in the middle
Earnings
WuXi AppTec Remains Resilient Amid Threat from BIOSECURE Act, Continues to Attract New Clients
As the Chinese contract manufacturer awaits the U.S. Senate’s consideration of the BIOSECURE Act, it has added 800 new customers in the first nine months of 2024, while being hit with a 2% revenue decline in the third quarter.
October 29, 2024
 · 
2 min read
 · 
Tristan Manalac
2D illustration of the gut with microorganisms
Inflammatory bowel disease
Lilly and J&J Face Off in Crohn’s Disease With Phase III Readouts at ACG 2024
Eli Lilly and Johnson & Johnson are seeking label expansions for Omvoh and Tremfya, respectively, in Crohn’s disease following approvals for ulcerative colitis. GlobalData projects total sales for Tremfya to reach $7.8 billion globally by 2029.
October 29, 2024
 · 
2 min read
 · 
Tristan Manalac
Career Advice
What You Need to Know to Become a Clinical Research Associate
A clinical research associate is a professional who oversees clinical trials. Here are our top tips on how to become one.
October 28, 2024
 · 
4 min read
 · 
Mark Terry
Psychological concept. Chaotic thought process
Business
AbbVie Doubles Down on Alzheimer’s With $1.4B Aliada Buy
The acquisition of Aliada Therapeutics gives AbbVie access to a Phase I anti-amyloid antibody as well as the biotech’s novel platform engineered for efficient blood-brain barrier transport.
October 28, 2024
 · 
2 min read
 · 
Heather McKenzie
Pictured: Novartis' logo outside its building in S
Collaboration
Novartis Inks Potential $2.2B Molecular Glue Deal With Monte Rosa
The Swiss pharma is paying $150 million upfront to gain rights to Monte Rosa’s VAV1-targeting molecular glue degraders, led by a Phase I candidate which holds therapeutic promise for immune-mediated diseases.
October 28, 2024
 · 
2 min read
 · 
Tristan Manalac
3D Illustration of a pancreas with tumors
Pancreatic cancer
Revolution Medicines Targets Hard-to-Treat Pancreatic Cancer With Two Early-Phase Readouts
Jefferies analyst Kelly Shi in a Sunday note to investors said that both data drops for Revolution Medicines’ experimental RAS inhibitors are positive and could be “synergistic” in the first-line setting for pancreatic ductal adenocarcinoma.
October 28, 2024
 · 
2 min read
 · 
Tristan Manalac
FDA signage at its headquarters in Maryland
Approvals
Iterum Wins FDA Approval For Oral UTI Antibiotic, Seeks ‘Strategic Transaction’ for Asset
Orlynvah is the first oral penem approved in the U.S. and Iterum Therapeutics’ first FDA-approved product. CEO Corey Fishman said the company will renew its efforts to look for a potential partner to maximize value for its stakeholders.
October 28, 2024
 · 
2 min read
 · 
Tristan Manalac
2D illustration of kidneys
IgA nephropathy
Biogen, Vertex Heat Up IgAN Arena With Mid-Stage Readouts at ASN 2024
William Blair analyst Myles Minter in a Monday note to investors said that Vertex’s povetacicept “has maintained its potential to be a best-in-class asset” in the IgA nephropathy space and could become a “multibillion-dollar pipeline-in-a-drug product” for autoimmune disorders, while “outstanding questions” remain for Biogen’s felzartamab before moving into pivotal studies.
October 28, 2024
 · 
3 min read
 · 
Tristan Manalac
searching for the virus cure medical pills in pattern on vibrant background
FDA
Evolving FDA Accelerated Approval Pathway Suffers Spate of Withdrawals
As therapies for rare and neurological diseases earn accelerated approval, experts laud the program’s intent while remaining concerned about confirmatory trials and clinical efficacy, especially as products greenlit under this pathway are pulled from the market.
October 28, 2024
 · 
7 min read
 · 
Heather McKenzie
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS